Cue Biopharma Announces Public Offering of Common Stock and Warrants Amid Strategic Focus on Autoimmune Therapeutics
By
BOSTON, September 26, 2024’ Cue Biopharma, Inc.(Nasdaq: CUE), a clinical-stage biopharmaceutical company specializing in the development of novel therapeutic biologics aimed at selectively engaging and modulating disease-specific T cells, announced today the initiation of an underwritten public offering of shares of its common stock.This offering also includes pre-funded warrants to purchase common stock, as well as accompanying warrants for the purchase of additional common stock.
In a statement, Cue Biopharma emphasized that the completion of the offering is contingent on market conditions, and there are no assurances regarding whether the offering will be executed or the size and terms if it does proceed.All securities involved in the offering will be issued by Cue Biopharma itself.
This move comes as part of a broader strategic agenda that the company delineated on July 25, 2024, which emphasizes its focus on developing autoimmune therapeutics.This new strategic vision aims to leverage Cue Biopharma’s innovative platforms to create significant value in biopharmaceutical development.
The company’s approach hinges on its proprietary Immuno-STATâ„¢ (Selective Targeting and Alteration of T cells) platform, which is designed to modulate the immune response precisely and specifically.This technology aims to distinguish between diseased and healthy cells, thus potentially reducing the side-effects linked to conventional immunotherapies.Such precision makes it particularly valuable in the treatment of autoimmune disorders, where the immune system mistakenly attacks the body’s own cells.
The funds generated from this offering are expected to fuel further research and development, as well as clinical trials that are crucial for bringing their advanced therapies to market.As of now, Cue Biopharma has been making strides in clinical development, with promising early-phase trials for diseases like Type 1 diabetes, rheumatoid arthritis, and other autoimmune conditions.
Today’s announcement marks a significant step in our ongoing efforts to advance our pipeline of innovative therapies, said Daniel Passeri, Chief Executive Officer of Cue Biopharma.With the additional resources, we are poised to accelerate our programs targeting autoimmune diseases, providing patients with novel treatment options that could potentially transform their lives.
Cue Biopharma, originally founded in 2014, has been at the forefront of researching T cell modulation.Investors and industry analysts alike are closely watching this stock offering, given the company’s promising pipeline and the high commercial potential of its therapeutic candidates.
The success of this offering, while uncertain, could mark a pivotal moment for Cue Biopharma, propelling its objectives and vision in the biopharmaceutical landscape.The company’s ultimate goal is to achieve a platform capable of treating a wide array of diseases by fine-tuning immune responses in a way that maximizes efficacy and minimizes adverse effects.
By focusing on selective immune modulation, Cue Biopharma aims to address significant unmet medical needs in the realm of autoimmune diseases, potentially paving the way for next-generation therapies that bring hope to millions of patients worldwide.
As the details of the offering unfold, stakeholders are advised to stay tuned for further information.
Comments